LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its US subsidiary Greenwich Biosciences, announced today that new results from completed Phase 3 trials of Epidiolex® (cannabidiol or CBD) in Lennox-Gastaut syndrome (LGS) and Dravet syndrome, along with other supportive data, will be presented at the American Epilepsy Society (AES) Annual Meeting, December 1-5, 2017, in Washington D.C.
Abstracts released today include the following highlights:
- Responder analyses from pooled Phase 3 data of LGS patients on/off clobazam
- Data from two expanded access sites in patients on/off clobazam
- Long-term maintenance treatment effect and safety in the open label extension study and the expanded access program
- Exposure-response analysis of CBD in Phase 3 LGS studies
“We continue to see a robust flow of data from the Epidiolex clinical